

# Betty Y S Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/904857/publications.pdf>

Version: 2024-02-01

59  
papers

9,109  
citations

117625

34  
h-index

128289

60  
g-index

62  
all docs

62  
docs citations

62  
times ranked

15141  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nanoparticle-mediated cellular response is size-dependent. <i>Nature Nanotechnology</i> , 2008, 3, 145-150.	31.5	2,452
2	Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. <i>Nature</i> , 2002, 417, 74-78.	27.8	1,023
3	Nanomedicine. <i>New England Journal of Medicine</i> , 2010, 363, 2434-2443.	27.0	987
4	Phagocytosis checkpoints as new targets for cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 568-586.	28.4	557
5	Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. <i>Nature Biomedical Engineering</i> , 2020, 4, 69-83.	22.5	415
6	Improving immune-vascular crosstalk for cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 195-203.	22.7	340
7	Breaking Down the Barriers to Precision Cancer Nanomedicine. <i>Trends in Biotechnology</i> , 2017, 35, 159-171.	9.3	254
8	Designing nanomedicine for immuno-oncology. <i>Nature Biomedical Engineering</i> , 2017, 1, .	22.5	178
9	Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. <i>Scientific Reports</i> , 2016, 6, 26269.	3.3	167
10	Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 2104-2115.	8.2	152
11	On the issue of transparency and reproducibility in nanomedicine. <i>Nature Nanotechnology</i> , 2019, 14, 629-635.	31.5	149
12	Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. <i>Nature Communications</i> , 2020, 11, 1508.	12.8	138
13	Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. <i>Nature Nanotechnology</i> , 2017, 12, 763-769.	31.5	136
14	Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles. <i>ACS Nano</i> , 2015, 9, 8689-8696.	14.6	134
15	Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. <i>Nature Communications</i> , 2022, 13, 767.	12.8	128
16	Immunomodulating Nanomedicine for Cancer Therapy. <i>Nano Letters</i> , 2018, 18, 6655-6659.	9.1	121
17	Immune Priming of the Tumor Microenvironment by Radiation. <i>Trends in Cancer</i> , 2016, 2, 638-645.	7.4	120
18	Biodegradable Quantum Dot Nanocomposites Enable Live Cell Labeling and Imaging of Cytoplasmic Targets. <i>Nano Letters</i> , 2008, 8, 3887-3892.	9.1	116

#	ARTICLE	IF	CITATIONS
19	Advances and challenges of nanotechnology-based drug delivery systems. <i>Expert Opinion on Drug Delivery</i> , 2007, 4, 621-633.	5.0	108
20	How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation. <i>Nature Biomedical Engineering</i> , 2018, 2, 797-809.	22.5	99
21	The Reciprocity between Radiotherapy and Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 1709-1717.	7.0	95
22	Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery. <i>Advanced Science</i> , 2019, 6, 1802070.	11.2	82
23	Nanotechnology platforms for cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1590.	6.1	82
24	Tumor Vasculatures: A New Target for Cancer Immunotherapy. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 613-623.	8.7	79
25	S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma. <i>Cancer Research</i> , 2017, 77, 5360-5373.	0.9	78
26	Considerations for designing preclinical cancer immune nanomedicine studies. <i>Nature Nanotechnology</i> , 2021, 16, 6-15.	31.5	77
27	Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 1712-1724.	7.0	76
28	Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles. <i>Nature Nanotechnology</i> , 2022, 17, 891-899.	31.5	74
29	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. <i>Radiotherapy and Oncology</i> , 2017, 125, 80-88.	0.6	58
30	Vascular ApoE4 Impairs Behavior by Modulating Gliovascular Function. <i>Neuron</i> , 2021, 109, 438-447.e6.	8.1	42
31	Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2007576.	21.0	42
32	The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. <i>Practical Radiation Oncology</i> , 2016, 6, 241-247.	2.1	41
33	The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCCDB. <i>Oncotarget</i> , 2016, 7, 24848-24859.	1.8	40
34	Lessons from immuno-oncology: a new era for cancer nanomedicine?. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 369-370.	46.4	37
35	Extracellular Vesicles: An Emerging Nanoplatfrom for Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 606906.	2.8	36
36	Pazopanib therapy for cerebellar hemangioblastomas in von Hippelâ€Lindau disease. <i>Targeted Oncology</i> , 2012, 7, 145-149.	3.6	34

#	ARTICLE	IF	CITATIONS
37	Folate Receptor-Targeted Albumin Nanoparticles Based on Microfluidic Technology to Deliver Cabazitaxel. <i>Cancers</i> , 2019, 11, 1571.	3.7	34
38	Spatiotemporal Immunomodulation Using Biomimetic Scaffold Promotes Endochondral Ossification-Mediated Bone Healing. <i>Advanced Science</i> , 2021, 8, e2100143.	11.2	33
39	Assessing Near-Infrared Quantum Dots for Deep Tissue, Organ, and Animal Imaging Applications. <i>Journal of the Association for Laboratory Automation</i> , 2008, 13, 6-12.	2.8	30
40	Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 439-445.	2.5	30
41	Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. <i>Journal of Neuro-Oncology</i> , 2014, 118, 405-412.	2.9	28
42	Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. <i>Head and Neck</i> , 2016, 38, E1459-66.	2.0	28
43	Cerebral Venous Thrombosis Associated with Intracranial Hemorrhage and Timing of Anticoagulation after Hemicraniectomy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2016, 25, 2312-2316.	1.6	23
44	Membrane TLR9 Positive Neutrophil Mediated MPLA Protects Against Fatal Bacterial Sepsis. <i>Theranostics</i> , 2019, 9, 6269-6283.	10.0	22
45	Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016. <i>JAMA Network Open</i> , 2020, 3, e2028627.	5.9	22
46	The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update. <i>Journal of Neuro-Oncology</i> , 2020, 150, 215-267.	2.9	19
47	Self-Assembled pH-Sensitive Polymeric Nanoparticles for the Inflammation-Targeted Delivery of Cu/Zn-Superoxide Dismutase. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 18152-18164.	8.0	14
48	Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma. <i>Oncotarget</i> , 2016, 7, 32156-32171.	1.8	14
49	Non-contiguous meningeal metastases of olfactory neuroblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 126, 201-203.	2.9	13
50	Immune landscape of a genetically engineered murine model of glioma compared with human glioma. <i>JCI Insight</i> , 2022, 7, .	5.0	10
51	Advanced Immunotherapy Approaches for Glioblastoma. <i>Advanced Therapeutics</i> , 2021, 4, 2100046.	3.2	8
52	Visualization of Hepatocellular Regeneration in Mice After Partial Hepatectomy. <i>Journal of Surgical Research</i> , 2019, 235, 494-500.	1.6	6
53	Perspectives of Nanotechnology in the Management of Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 32, 196-210.	1.3	4
54	Strategies of Perturbing Ion Homeostasis for Cancer Therapy. <i>Advanced Therapeutics</i> , 2022, 5, 2100189.	3.2	3

#	ARTICLE	IF	CITATIONS
55	Study of Osteocyte Behavior by High-Resolution Intravital Imaging Following Photo-Induced Ischemia. <i>Molecules</i> , 2018, 23, 2874.	3.8	2
56	Cancer Stem Cells, not Bulk Tumor Cells, Determine Mechanisms of Resistance to SMO Inhibitors. <i>Cancer Research Communications</i> , 2022, 2, 402-416.	1.7	2
57	Harnessing cGAS&#x2013;STING Pathway for Cancer Immunotherapy: From Bench to Clinic. <i>Advanced Therapeutics</i> , 2022, 5, .	3.2	2
58	Challenges and opportunities of nanotechnology in cancer immunotherapy. , 2022, , 197-239.		1
59	Cancer nanomedicines for enhanced immunotherapy. , 2022, , .		0